Dr. David L. Grinblatt
Claim this profileNorthShore University HealthSystem-Evanston Hospital
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Lymphoid Leukemia
6 reported clinical trials
20 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
13q positive
13q negative
12 positive
2Lymphoid Leukemia
13q positive
13q negative
12 positive
Affiliated Hospitals
Clinical Trials David L. Grinblatt is currently running
Blinatumomab + Chemotherapy
for Leukemia
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Recruiting2 awards Phase 310 criteria
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting1 award Phase 217 criteria
More about David L. Grinblatt
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments David L. Grinblatt has experience with
- Venetoclax
- Cytarabine
- Obinutuzumab
- Dexamethasone
- Ibrutinib
- Daratumumab
Breakdown of trials David L. Grinblatt has run
T-Lymphoblastic Leukemia/Lymphoma
Lymphoid Leukemia
Lymphoma
Chronic Lymphocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David L. Grinblatt specialize in?
David L. Grinblatt focuses on T-Lymphoblastic Leukemia/Lymphoma and Lymphoid Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved 13q positive patients, or patients who are 13q negative.
Is David L. Grinblatt currently recruiting for clinical trials?
Yes, David L. Grinblatt is currently recruiting for 4 clinical trials in Evanston Illinois. If you're interested in participating, you should apply.
Are there any treatments that David L. Grinblatt has studied deeply?
Yes, David L. Grinblatt has studied treatments such as Venetoclax, Cytarabine, Obinutuzumab.
What is the best way to schedule an appointment with David L. Grinblatt?
Apply for one of the trials that David L. Grinblatt is conducting.
What is the office address of David L. Grinblatt?
The office of David L. Grinblatt is located at: NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois 60201 United States. This is the address for their practice at the NorthShore University HealthSystem-Evanston Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.